Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy

International Journal of Artificial Organs

Volumn 32, Issue 6, 2009, Pages 371-380

  Tsai, Meng Kun ^a   Wu, Fe Lin Lin ^a,b   Lai, I Rue ^a   Lee, Chih Yuan ^a   Hu, Rey Heng ^a   Lee, Po Huang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acute rejection; Calcineurin inhibitor; CN: minimization; Graft survival; Kidney transplantation; Sirolimus

Indexed keywords

DRUG PRODUCTS; GRAFTING (CHEMICAL); GRAFTS; MULTIVARIANT ANALYSIS;

ACUTE REJECTION; CALCINEURIN INHIBITORS; CN: MINIMIZATION; GRAFT SURVIVAL; INDUCTION THERAPY; KIDNEY TRANSPLANTATION; MINIMISATION; RENAL TRANSPLANTS; SIROLIMUS; TACROLIMUS;

ANTIBODIES;

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; INSULIN; LIVER ENZYME; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; INCISIONAL HERNIA; INFECTION; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEG SWELLING; LEUKOCYTE COUNT; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG HEMORRHAGE; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TRIACYLGLYCEROL BLOOD LEVEL; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA;

EID: 70149087539     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200608     Document Type: Article

References (23)

1. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-26.
2. Nankivell B, Borrow R, Fung CI, et al. The natural history of chronic allograft nephropathy. New Engl J Med 2003; 349: 2326-33.
3. Nankivell B, Borrow R, Fung CI, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-65.
4. Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-48.
5. Vitko S, Wlodarczyk Z, Kyllonen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006; 6: 531-8.
6. Tsai M-K, Lee C-Y, Hu R-H, Lee P-H. Sirolimus add-on rescue therapy can benefit patients with chronic renal allograft dysfunction. J Formos Med Assoc 2003; 102: 863-7.
7. Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 1826-35.
8. Moreso F, Lopea M, Vallejos A, et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 82-8.
9. Tsai M-K, Hu R-H, Lee C-J, Lee P-H. Prognostic significance of six-month estimated glomerular filtration rate in cadaveric renal transplantation. J Formos Med Assoc 2005; 10: 180-4.
10. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Brenham BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-8.
11. Kahan BD, Etheridge WB. Minimization of calcineurin inhibitors: a review of de-novo strategies and conversion algorithms. Curr Opin Organ Transplant 2007; 12: 624.
12. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Symphony: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-75.
13. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-22.
14. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586-94.
15. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-6.
16. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005; 5: 2531-8.
17. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-7.
18. Guerra G, Srinivas TR, Meier-Kriesche H-U. Calcineurin inhibi tor-free immunosuppression in kidney transplantation. Transplant Int 2007; 20: 813-827.
19. Abramowicz D, Del Carmen RM, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-40.
20. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-70.
21. Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006; 81: 1285-9.
22. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21: 460-5.
23. Champion L, Stern M, Israel-Biet D, et al. Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505-9.